Sinopharm to issue $1.61B in bonds; Chugai unveils 'promising' ACE910 data;

> Sinopharm Group plans to issue RMB10 billion ($1.61 billion) worth of bonds with maturities up to 10 years to reduce borrowing cost and to improve its debt structure. Release (PDF)

> Japan's Chugai Pharma unveiled "promising" data on bispecific antibody ACE910, which was initially developed by Chugai and was opted into by Roche ($RHHBY), at a conference of International Society on Thrombosis and Hemostasis in Toronto on Monday. Release

> San Diego-based Ambrx named Tiecheng (Alex) Qiao as CEO and announced that Feng Tian, formerly vice president of science and technology, China, has been promoted to the newly-created position of chief science officer. Release

> Australia-listed Benitec Biopharma announced a new exploratory cellular therapy program including exosome-based delivery using proprietary ddRNAi technology as part of a collaboration with U.K.-based stem cell therapeutics company, ReNeuron. Release

> India's Natco Pharma says it is waiting on U.S. FDA to get nod for generic Copaxone launch after U.S. Court of Appeals finds Teva's ($TEVA) 808 Copaxone patent invalid. Release (PDF)

> India's Aurigene plans to develop, sell anti-infective drugs on its own. Report

> The state-run Indian Institute of Chemical Technology plans to work with domestic drugmakers to develop local substitutes for life-saving drugs paracetamol, ibuprofen, ciprofloxacin. Report

> Novasep has signed two partnership agreements for the Japanese markets, one with Allied Laboratories, a life science and chemical consulting company, and one with AR Brown to represent Novasep's CMO services in Japan. Release

> India's Aurobindo Pharma receives U.S. FDA approval on azithromycin jab. Release (PDF)

> Drug firm Dr. Reddy's Laboratories said it has completed the acquisition of select portfolio of established brands of Belgian firm UCB in India. Report

> Johnson & Johnson ($JNJ) Innovation and WuXi AppTec ($WX) will develop a China life science incubator as part of the U.S. firm's 17 new collaborations with research institutions and healthcare companies announced last week. Release

> Shanghai Fosun Pharma aims to get 40% of its revenues outside of-China sources by 2020, more than triple last year's figure of 12% by spurring management through a stake in the firm. Report

> Pfizer ($PFE) started construction of a $95 million consumer health products manufacturing plant in Suzhou and also plans an R&D facility on the site home to an existing plant. Release

> Taipei-listed ScinoPharm Taiwan said it will manufacture celecoxib, a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient at its China FDA GMP certified plant and work with China's Raffles PharmaTech on R&D in order for both firms to exploit greater business opportunities in the U.S. market. Release

> India's Intas Pharmaceuticals said the U.S. FDA has accepted its peg filgrastim biosimilar for filing under the 351(k) abbreviated approval pathway created by the Biosimilar Price Competition and Innovation Act. Release

> Japan's Eisai said its U.S. unit won FDA approval for an indication expansion of Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. Release

> Medical device maker Owen Mumford opened a new Asia-Pacific hub in Nusajaya in southern Malaysia that will enhance its packaging services and provide additional warehousing within the region. Release

> India's Jubilant Life Sciences gets U.S. FDA ANDA approval for levofloxacin tablets. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.